MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, SGMT had -$40,819K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$40,819K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Sales and maturities of marketab...
    • Stock-based compensation expense
    • Accounts payable, accrued expens...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Prepaid expenses and other curre...
    • Accretion of discount on marketa...
    • Operating lease liabilities

Cash Flow
2025-12-31
Net loss
-51,038
Accretion of discount on marketable securities
389
Non-cash operating lease expense
151
Stock-based compensation expense
6,449
Write-off of deferred financing costs
230
Prepaid expenses and other current assets
1,830
Accounts payable, accrued expenses and other current liabilities
929
Operating lease liabilities
-152
Net cash used in operating activities
-45,650
Purchases of marketable securities
106,864
Sales and maturities of marketable securities
111,420
Net cash provided by (used in) investing activities
4,556
Proceeds from sale of series a common stock, net of issuance costs
0
Payment of financing costs
0
Proceeds from exercise of stock options
275
Net cash provided by financing activities
275
Net (decrease) increase in cash and cash equivalents
-40,819
Cash and cash equivalents at beginning of period
75,840
Cash and cash equivalents at end of period
35,021
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Sales and maturitiesof marketable...$111,420K Proceeds from exercise ofstock options$275K Net cash provided by(used in) investing...$4,556K Net cash provided byfinancing activities$275K Canceled cashflow$106,864K Net (decrease)increase in cash and cash...-$40,819K Canceled cashflow$4,831K Stock-based compensationexpense$6,449K Accounts payable,accrued expenses and...$929K Write-off of deferredfinancing costs$230K Non-cash operating leaseexpense$151K Purchases of marketablesecurities$106,864K Net cash used inoperating activities-$45,650K Canceled cashflow$7,759K Net loss-$51,038K Prepaid expenses andother current assets$1,830K Accretion of discount onmarketable securities$389K Operating leaseliabilities-$152K

Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Inc. (SGMT)